Starting July 1, Medicare will offer a new GLP-1 Bridge program that will significantly reduce the cost of weight-loss drugs for eligible seniors. Under this new program, beneficiaries will be able to obtain popular GLP-1 agonists such as Wegovy and Zepbound for a monthly copay of $50.
This initiative aims to make obesity treatments more accessible to the senior population, addressing a key concern for many individuals managing their health. The GLP-1 drugs are a class of medication that has shown effectiveness in weight management and is also used for managing type 2 diabetes.